约翰逊 &安培; 约翰逊执行官: 我们将免除 100 销往美国的百万种疫苗. by summer
约翰逊 &安培; 约翰逊执行博士. Paul Stoffels gives an update to ‘America’s Newsroom’ on the company’s single-dose vaccine and how soon it hopes to receive emergency authorization.
约翰逊 & Johnson announced on Friday that it had submitted its 新冠病毒 vaccine to the World Health Organization for emergency use listing. 的 疫苗, which is administered in a one-dose jab, is also pending emergency use authorization from the FDA.
“Our filing with the World Health Organization marks another important step in our effort to combat COVID-19 and also in our unwavering commitment to equitable access,” Paul Stoffels, 约翰逊 & Johnson vice chairman of the executive committee, and chief scientific officer, 在新闻稿中说. “If we are to end the global pandemic, life-saving innovations like vaccines must be within reach for all countries.”
The company submitted data including interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial, which reflected 66% effectiveness overall in preventing moderate-to-severe COVID-19 28 days after vaccination. While the efficacy is lower than Pfizer and BioNTech’s 95%, officials said it still provides a degree of protection much higher than the threshold needed to have an impact.
PFIZER COVID-19 VACCINE 85% EFFECTIVE AFTER SINGLE DOSE, ISRAELI RESEARCHERS FIND
例如, the annual flu vaccine is typically between 40% 和 60% 有效.
The company is hoping that the emergency use listing would streamline the process of providing supply to COVAX, which would help distribute vaccines to lower-income countries. The company previously reached an agreement to supply COVAX with up to 500 million doses of the vaccine through 2022.
It was not clear when WHO would issue a decision on J&J’s request, and the FDA is not scheduled to meet to discuss the vaccine until Feb. 26.
